About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04822623

Imaging Evaluation of Central Nervous Autoimmune Diseases

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people. Neuromyelitis opti...

Lead sponsor: Qilu Hospital of Shandong University•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Xaoyu Han

CONTACT

18560081083 710804284@qq.com

Anning Li

CONTACT

18560080268 anningli00@163.com

Sponsors

Lead Sponsor

Qilu Hospital of Shandong University

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. 18-65 years old;
•2. Nmosd was diagnosed according to wingerchuk standard revised in 2015, MS was diagnosed according to McDonald standard revised in 2017, and 100 normal people were diagnosed;
•3. In the acute stage, within 1 month of the onset or stable stage, there was no GD enhanced lesion on MRI, and EDSS score had no significant change within 6 months, which was more than 1 month from the last attack;
•4. MRI examination was complete: baseline, 6 months, 1 year, 2 years;
•5. Sign informed consent.

Exclusion Criteria

•1. The course of disease was more than 30 years;
•2. History of brain injury or spinal cord injury;
•3. History of central nervous system infection or immunodeficiency syndrome;
•4. HBV, HCV patients, syphilis, HIV-1, HIV-2 patients;
•5. Suffering from mental illness;
•6. Pregnant and lactating women or patients planning to conceive within one year;
•7. Unable to cooperate to complete the follow-up due to geographical or other reasons;
•8. Patients also participated in other randomized controlled trials.

Related studies

RECRUITINGEARLY Phase 1

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

NCT05145361 · NMO Spectrum Disorder

Biorepository and Registry for Plasma Exchange Patients

NCT05004493 · Antibody-mediated Rejection, NMO Spectrum Disorder, and more

China National Registry of Neuro-Inflammatory Diseases

NCT05154370 · Multiple Sclerosis, NMO Spectrum Disorder, and more

Enrolling By Invitation

Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy

NCT07521384 · Traumatic Brain Injury, Cerebral Palsy, and more

Active Not RecruitingPhase 2/3

Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

NCT05403138 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 30, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment300

Start dateMay 2021

Last updatedMar 30, 2021

Condition

MS (Multiple Sclerosis)NMO Spectrum Disorder

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 30, 2021Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions